Impact of secondary hyperparathyroidism on disease progression, healthcare resource utilization and costs in pre-dialysis CKD patients

Current Medical Research and Opinion

Volumn 24, Issue 11, 2008, Pages 3037-3048

  Schumock, Glen T ^a   Andress, Dennis ^b   Marx, Steven E ^b   Sterz, Raimund ^b   Joyce, Amie T ^c   Kalantar Zadeh, Kamyar ^d  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^b ABBOTT LABORATORIES   (United States)

^c PharMetrics Inc   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Chronic kidney disease; Costs; Hyperparathyroidism; Utilization

Indexed keywords

VITAMIN D RECEPTOR;

ADULT; AGED; CHRONIC KIDNEY DISEASE; CLINICAL FEATURE; COHORT ANALYSIS; COMORBIDITY; CONFERENCE PAPER; CONTROLLED STUDY; DISEASE COURSE; FEMALE; GEOGRAPHIC DISTRIBUTION; GROUPS BY AGE; HEALTH CARE COST; HEALTH CARE UTILIZATION; HEALTH INSURANCE; HEMODIALYSIS; HOSPITAL PATIENT; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL SPECIALIST; MORTALITY; OUTCOME ASSESSMENT; PHYSICIAN; RETROSPECTIVE STUDY; SECONDARY HYPERPARATHYROIDISM; SEX DIFFERENCE;

ADULT; AGED; AGED, 80 AND OVER; ALGORITHMS; CASE-CONTROL STUDIES; COHORT STUDIES; DISEASE PROGRESSION; FEMALE; HEALTH CARE COSTS; HEALTH RESOURCES; HUMANS; HYPERPARATHYROIDISM, SECONDARY; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; RENAL DIALYSIS; UNITED STATES;

EID: 67649408930     PISSN: 03007995     EISSN: 14734877     Source Type: Journal    
DOI: 10.1185/03007990802437943     Document Type: Conference Paper

References (32)

1. Malluche HH, Ritz E, Lange HP, et al. Bone histology in incipient and advanced renal failure. Kidney Int. 1976;9:355-362
2. Pitts TO, Piraino BH, Mitro R, et al. Hyperparathyroidism and 1,25-dihydroxyvitamin D deficiency in mild, moderate, and severe renal failure. J Clin Endocrinol Metab 1988;67:876-881 (Pubitemid 18277204)
3. Llach F, Yudd M. Pathogenic, clinical, and therapeutic aspects of secondary hyperparathyroidism in chronic renal failure. Am J Kidney Dis 1998;32:S3-12 (Pubitemid 28487831)
4. Negri AL, Barone R, Quiroga MA, et al. Bone mineral density: serum markers of bone turnover and their relationships in peritoneal dialysis. Perit Dial Int 2004;24:163-168 (Pubitemid 38515080)
5. Palmer SC, Strippoli GF, McGregor DO. Interventions for preventing bone disease in kidney transplant recipients: a systematic review of randomized controlled trials. Am J Kidney Dis 2005;45:638-649 (Pubitemid 40460752)
6. Terzibasioglu AM, Akarirmak U, Saridogan M, et al. Correlation of back pain, compression fracture and quadriceps muscle strength with bone mineral density in renal insufficiency patients. Eura Medicophys 2005;41:303-308 (Pubitemid 43171454)
7. Collins AJ, Kasiske B, Herzog C, et al. Excerpts from the United States Renal Data System 2004 annual data report: atlas of end-stage renal disease in the United States. Am J Kidney Dis 2005;45:A5-7
8. Foley RN, Murray AM, Li S, et al. Chronic kidney disease and the risk for cardiovascular disease, renal replacement, and death in the United States Medicare population, 1998 to 1999. J Am Soc Nephrol 2005;16:489-495
9. Danese MD, Kim J, Doan QV, et al. PTH and the risks for hip, vertebral, and pelvic fractures among patients on dialysis. Am J Kidney Dis 2006;47:149-156 (Pubitemid 41828277)
10. Johnson ES, Smith DH, Thorp ML, et al. Elevated intact parathyroid hormone levels and health care costs and utilization: retrospective cohort of patients with chronic kidney disease. Value Health 2006;9:A96 [abstract]
11. Robbins JD, Kim JJ, Zdon G, et al. Resource use and patient care associated with chronic kidney disease in a managed care setting. J Managed Care Pharm 2003;9:238-247
12. Keith DS, Nichols GA, Gullion CM, et al. Longitudinal followup and outcomes among a population with chronic kidney disease in a large managed care organization. Arch Intern Med 2004;164:659-663 (Pubitemid 38392981)
13. Andress DL. Vitamin D in chronic kidney disease: a systemic role for selective vitamin D receptor activation. Kidney Int 2006;69:33-43 (Pubitemid 43117736)
14. St. Peter WL, Lewis MJ, Collins AJ. End-stage renal disease. In: DiPiro JT, Talbert RL, Yee GC, et al., eds. Pharmacotherapy: a patholphysiologic approach, 5th edn. New York: McGraw-Hill, 2002 pp.815-42
15. Joy MS, Karagiannis PC, Peyerl FW. Outcomes of secondary hyperparathyroidism in chronic kidney disease and the direct costs of treatment. J Manag Care Pharm 2007;13:397-411 (Pubitemid 47162414)
16. 2003 ICD-9-CM professional for physicians - Volumes 1 & 2, 6th edn. Reston VA: Ingenix, 2003
17. Charlson ME, Pompei P, Ales KL, et al. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chron Dis 1987;40:373-383 (Pubitemid 17055592)
18. Joyce AT, Iacoviello JM, Nag S, et al. End-stage renal disease-associated managed care costs among patients with and without diabetes. Diabetes Care 2004;27:2829-2835 (Pubitemid 39565045)
19. Kahn S. Secondary hyperparathyroidism is associated with high cost of care among chronic kidney disease patients with cardiovascular disease comorbidities. Nephron Clin Pract 2007;105:C159-64
20. Horl WH. The clinical consequences of secondary hyperparathyroidism: focus on clinical outcomes. Nephrol Dial Transplant 2004;19:V2-8 (Pubitemid 39214193)
21. Friedman TC, Norris KC. The role of vitamin D in mild to moderate chronic kidney disease. Trends Endocrinol Metab 2002;13:189-194 (Pubitemid 36733978)
22. Ho LT, Sprague SM. Renal osteodystrophy in chronic renal failure. Semin Nephrol 2002;22:488-493 (Pubitemid 35351261)
23. Moe SM, Chen NX. Inflammation and vascular calcification. Blood Purif 2005;23:64-71 (Pubitemid 40082246)
24. Floege J, Ketteler M. Vascular calcification in patients with end-stage renal disease. Nephrol Dial Transplant 2004;19:V59-66 (Pubitemid 39214202)
25. Block GA, Klassen PS, Lazarus JM, et al. Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. J Am Soc Nephrol 2004;15:2208-2218 (Pubitemid 39031360)
26. Go AS, Chertow GM, Fan D, et al. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 2004;351:1296-1305 (Pubitemid 39268908)
27. Tokumoto M, Tsuruya K, Fukuda K, et al. Parathyroid cell growth in patients with advanced secondary hyperparathyroidism: vitamin D receptor and cyclin-dependent kinase inhibitors, p21 and p27. Nephrol Dial Transplant 2003;18:iii9-12 (Pubitemid 36826917)
28. Tominaga Y, Kohara S, Namii Y, et al. Clonal analysis of nodular parathyroid hyperplasia in renal hyperparathyroidism. World J Surg 1996;20:744-750 (Pubitemid 26281898)
29. Coresh J, Astor BC, Greene T, et al. Prevalence of chronic kidney disease and decreased kidney function in the adult US population: Third National Health and Nutrition Examination Survey. Am J Kidney Dis 2003;41:1-12 (Pubitemid 36043346)
30. Levin A, Bakris GL, Molitch M, et al. Prevalence of abnormal serum vitamin D, PTH, calcium, and phosphorus in patients with chronic kidney disease: results of the study to evaluate early kidney disease. Kidney Int 2007;71:31-38 [epub ahead of print 8 Nov 2006] (Pubitemid 44967731)
31. Pelletier EM, Shim B, Goodman S, et al. Epidemiology and economic burden of brain metastases among patients with primary breast cancer: results from a US claims data analysis. Breast Cancer Res Treat 2008;108:297-305 [epub ahead of print 19 Jun 2007] (Pubitemid 351311367)
32. Fintel D, Joyce A, Mackell J, et al. Reduced mortality rates after intensive statin therapy in managed-care patients. Value Health 2007;10:161-169 (Pubitemid 46481143)